Free cash flow remains inconsistent, with margins ranging from a negative 1.8% in 2024Q4 to a peak of 13.7% in 2025Q3, reflecting erratic cash conversion cycles.
| Cash from Operations | 88M | 70.7M | 51.2M | 48.4M | 80.1M | 123.3M | 24.9M |
| Operating CF Margin % | - | 6.67% | 4.95% | 4.63% | 7.48% | 11.14% | 2.31% |
| Operating CF Growth % | 347.48% | 38.09% | 5.79% | -39.58% | -35.04% | 395.18% | - |
| Net Income | -3.2M | -2.6M | -154M | -80.5M | -38.3M | 112.9M | 75M |
| Depreciation & Amortization | 20.8M | 22.5M | 31.5M | 30.9M | 33M | 36.9M | 40M |
| Stock-Based Compensation | 16.5M | 16.6M | 11.7M | 8.9M | 9.2M | 3.6M | 0 |
| Deferred Taxes | 500K | 0 | -5.7M | -11.6M | -4.3M | 8.6M | 18.5M |
| Other Non-Cash Items | 51.7M | 30.4M | 162.6M | 89M | 109.7M | -5.9M | 3.5M |
| Working Capital Changes | -400K | 3.8M | 5.1M | 11.7M | -29.2M | -32.8M | -112.1M |
| Change in Receivables | 6.5M | 5.2M | 15.5M | -14.6M | 21.6M | -24.8M | -32.9M |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 600K | 2.6M | -1M | 3.8M | 200K | -700K | -500K |
| Cash from Investing | -6.7M | 16.7M | -2.4M | -5.3M | -42.3M | -119.2M | -3M |
| Capital Expenditures | -7.1M | -4.9M | -3.8M | -3.5M | -7.1M | -4.3M | -3.6M |
| CapEx % of Revenue | 0.67% | 0.46% | 0.37% | 0.33% | 0.66% | 0.39% | 0.33% |
| Acquisitions | 0 | 0 | 0 | -2.8M | -36.3M | -117.5M | -1.1M |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 300K | 19.8M | 1.4M | 1M | 1.1M | 2.6M | 1.7M |
| Cash from Financing | -70.6M | -72.2M | -48.3M | -40.5M | -18.6M | -36.1M | -16.7M |
| Debt Issued (Net) | -64.5M | -67.7M | -43.6M | -33.4M | 575M | -7.2M | 5.1M |
| Equity Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 124M |
| Dividends Paid | 0 | 0 | 0 | 0 | -654.9M | -154.1M | -144.5M |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -6.1M | -4.5M | -4.7M | -7.1M | 61.3M | 125.2M | -1.3M |
| Net Change in Cash | 10.7M | 15.2M | 500K | 2.6M | 19.2M | -32M | 40M |
| Free Cash Flow | 80.9M | 65.8M | 47.4M | 44.9M | 73M | 119M | 21.7M |
| FCF Margin % | 7.6% | 6.21% | 4.58% | 4.29% | 6.82% | 10.75% | 2.01% |
| FCF Growth % | 63.43% | 38.82% | 5.57% | -38.49% | -38.66% | 448.39% | - |
| FCF per Share | 1.53 | 1.30 | 0.94 | 0.90 | 1.46 | 30.51 | 5.56 |
| FCF Conversion (FCF/Net Income) | -25.28x | -15.37x | -0.33x | -0.60x | -1.98x | 1.11x | 0.33x |
| Interest Paid | 7.9M | 0 | 0 | 0 | 13.1M | 200K | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 11.9M | 28.4M | 0 |
Medicare Advantage reimbursement compression
According to quarterly cash flow statements, the relationship between net income and operating cash flow is highly erratic, with OCF/NI ratios swinging from 86.50 in 2024Q1 to -0.11 in 2025Q4, suggesting that reported net income is a poor proxy for the company's actual cash-generating capacity.
The extreme divergence between accounting profits and cash flow indicates that non-cash charges and working capital fluctuations are heavily distorting the bottom line. Investors should monitor whether this instability reflects genuine operational friction or merely the accounting noise inherent in the company's post-spin-off transition.
As reported in financial filings, Enhabit's free cash flow margins have demonstrated significant inconsistency, ranging from a negative 1.8% in 2024Q4 to a peak of 13.7% in 2025Q3, highlighting the difficulty in maintaining a predictable cash conversion cycle amidst ongoing operational and reimbursement headwinds.
The lack of a stable FCF trajectory suggests that the company's cash generation is highly sensitive to episodic revenue timing and labor-related cost spikes. This volatility warrants further investigation into whether the business can achieve sustainable cash flow growth without relying on favorable working capital swings.
Based on recent SEC filings, Enhabit maintains a remarkably low capital intensity, with CapEx/Revenue ratios consistently remaining below 1% over the last ten quarters, which effectively preserves cash flow for operational needs despite the company's broader challenges in achieving consistent profitability and margin expansion.
The low level of capital expenditure suggests that the business model is not asset-heavy, which provides a degree of protection against liquidity crunches. However, investors should consider whether this minimal investment level is sufficient to maintain the clinical quality and technology infrastructure required to compete for Medicare Advantage contracts.
As evidenced by the quarterly data, working capital changes have been a primary driver of cash flow volatility, with shifts ranging from a $17.9 million inflow in 2025Q3 to a $14.9 million outflow in 2025Q4, indicating that cash availability is heavily dependent on collection cycles.
The reliance on working capital fluctuations to bolster operating cash flow suggests that the company's underlying cash generation is less robust than headline figures might imply. This pattern may indicate challenges in managing accounts receivable, particularly as the payer mix shifts toward more complex Medicare Advantage plans.
Quick answers to the most common questions about buying EHAB stock.
Enhabit, Inc. (EHAB) generated $70.7M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Enhabit, Inc. (EHAB) generated $65.8M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.
Enhabit, Inc. (EHAB) spent $4.9M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.